Today: 21 May 2026
DroneShield stock jumps 18% as ASX:DRO taps Louis Gamarra as chief commercial officer
6 January 2026
1 min read

DroneShield stock jumps 18% as ASX:DRO taps Louis Gamarra as chief commercial officer

Sydney, January 6, 2026, 16:58 AEDT — Market closed

  • DroneShield shares closed up 18.1% at A$3.91, extending a strong start to 2026.
  • The company promoted sales executive Louis Gamarra to chief commercial officer.
  • Investors now look to the next earnings update for clues on demand conversion and margins.

DroneShield Limited (ASX:DRO) shares jumped 18.1% on Tuesday and ended at A$3.91, after rising as much as 20% intraday. Turnover climbed to about 32.0 million shares, more than double Monday’s volume.

The move matters because DroneShield is trying to prove it can scale sales execution as demand for counter-drone systems rises. Counter-drone, also known as counter‑uncrewed aerial systems (C‑UAS), refers to equipment and software used to detect, track and disrupt small drones.

DroneShield said it promoted Louis Gamarra to chief commercial officer, tasking him with leading global sales strategy and its distributor network. Investors have been trading the stock as a momentum name, and staffing changes in the go-to-market team can shift expectations on the timing of contract wins.

“As DroneShield continues to scale globally, strong commercial leadership is critical to turning demand into sustained performance,” chief executive Oleg Vornik said in a statement. droneshield.com

Tuesday’s rally added A$0.60 a share and left the stock up roughly 27% from its Dec. 31 close, based on the latest available prices. The stock traded between A$3.47 and A$3.98 during the session.

The gains came even as the benchmark S&P/ASX 200 slipped 0.5% at the close, underscoring the stock-specific bid behind DroneShield’s move.

For traders, the next technical test is whether the shares can hold above the A$3.80–A$3.90 area, after Tuesday’s surge and close near session highs. A$4.00 is the next psychological level, while Monday’s close around A$3.31 is a near-term reference point on the downside.

Still, DroneShield has been prone to sharp reversals. The stock slid heavily in late 2025 after investor concerns around executive share sales and disclosure practices, and any renewed questions on governance or contract timing could hit sentiment quickly.

Stock Market Today

  • Coca-Cola and Beverage Sector Show Mixed Q1 Performance with Vita Coco Leading Gains
    May 20, 2026, 9:22 PM EDT. As Q1 earnings wrap up, beverages, alcohol, and tobacco stocks report mixed results. The sector beat revenue estimates by 4.9%, though next-quarter guidance fell short by 0.6%. Coca-Cola (NYSE:KO) posted strong growth with $12.47 billion in revenue, exceeding estimates by 2.5%, and shares rose 7.7%. Leading the pack was Vita Coco (NASDAQ:COCO), with a 37.3% revenue surge and a 54.1% stock gain post-earnings. In contrast, Boston Beer (NYSE:SAM) saw a 4.4% revenue decline and missed on operating income forecasts, marking the weakest performance among peers. Shifting consumer trends and social media-driven lower brand launch costs are reshaping competition in the sector.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV
Previous Story

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears
Next Story

Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears

Go toTop